OPC Enrichment via Surface Marker Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for efficiently isolating, characterizing, and proliferating oligodendrocyte precursor cells (OPCs) for therapeutic applications, particularly in treating demyelinating diseases, due to limitations in selectively enriching and differentiating these cells for effective myelination.
Innovation Solution
The development of methods to enrich OPCs using specific surface markers such as PDGFRα, CD133, and CD105, followed by the use of antibodies and growth factors to isolate and proliferate these cells, enabling their differentiation into oligodendrocytes for transplantation and treatment of demyelinating diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional cell isolation methods are used, then cell separation is achieved, but the enrichment purity of oligodendrocyte precursor cells is insufficient
Solution Approach 1:
The patent applies parameter changes by utilizing specific surface marker expression profiles (PDGFRα+, CD105−, and A2B5lo/−) to distinguish and enrich OPCs from other neural precursor cells. This immunophenotypic parameter-based selection enables high-purity enrichment without complex procedural steps, directly resolving the contradiction between enrichment purity and method complexity.
2Productivity
If neural stem cells are cultured without specific selection, then cell proliferation occurs, but the population lacks specificity for oligodendrocyte differentiation
Solution Approach 1:
The patent extracts and selects only those neural precursor cells that exhibit the specific immunophenotype of OPCs (PDGFRα+, CD105−, A2B5lo/−) from the heterogeneous neural stem cell population. This selective extraction ensures that subsequent proliferation maintains both high productivity and reliable OPC specificity, enabling differentiated oligodendrocyte generation.
3Quantity of substance
If non-specific neural precursor cells are used, then cell availability is high, but differentiation efficiency into oligodendrocytes is low
Solution Approach 1:
The patent applies local quality by conferring unique identifying characteristics (immunophenotypic markers) to the target OPC population. Cells expressing PDGFRα+, CD105−, and A2B5lo/− are locally distinguished from other neural precursors, enabling selective enrichment that maintains quantity while ensuring high differentiation efficiency into oligodendrocytes through precise phenotypic specification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the effective enrichment and proliferation of OPCs, facilitating their differentiation into oligodendrocytes, which can be used to treat demyelinating diseases by promoting myelination and remyelination in the central nervous system.
Implementation Method 1
contacting a population of cells containing at least one OPC with a reagent that binds to the surface marker antigen expressed on the cell surface of an OPC
Data Source
AI summary
This application provides for enriched target populations oligodendrocyte precursor cells (OPCs) that can differentiate into oligodendrocytes. The target OPCs may be expanded and optionally subjected to conditions to induce their differentiation into oligodendrocytes. The target OPCs and their progeny are useful for the treatment of disease associated with demyelination of central nervous system axons.